INDV (Indivior Pharmaceuticals) Moat Score: 6/10 (As of Jun. 28, 2026)


INDV Indivior Pharmaceuticals Inc INDV
69 GF Score
Price $41.82
GF Value $22.98
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Moat Score?

Indivior Pharmaceuticals INDV +1.31% 69 Moat Score is 6 as of Jun. 28, 2026. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.98 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Indivior Pharmaceuticals ranks better than 97.09% on this metric.

Indivior Pharmaceuticals has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Indivior Pharmaceuticals has Narrow Moat: Indivior has a strong narrow moat with valuable patents and regulatory approvals in the pharmaceutical sector. It benefits from customer loyalty and some pricing power, but faces competition and lacks a wide distribution network or significant economies of scale.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Indivior Pharmaceuticals might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Indivior Pharmaceuticals  (NAS:INDV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Indivior Pharmaceuticals Moat Score Related Terms

INDV vs AMRX, KNSA, LQDA: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indivior Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Indivior Pharmaceuticals's Moat Score falls into.


INDV
69GF Score
Indivior Pharmaceuticals Inc INDV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Indivior Pharmaceuticals (INDV) has a Moat Score of 6 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Indivior Pharmaceuticals ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Indivior Pharmaceuticals' Moat Score too high?
Indivior Pharmaceuticals' current Moat Score is 6. Based on the distribution chart, Indivior Pharmaceuticals ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Moat Score compare to AMRX and KNSA?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #30 out of 1030 companies for Moat Score. This places Indivior Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Indivior Pharmaceuticals's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.98, compared to a current price of $41.82 — trading 82% above its estimated fair value. The current Moat Score is 6. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Moat Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.82 is trading 82% above its estimated GF Value™ of $22.98. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Moat Score: 6
  • GF Value™: $22.98 vs. price of $41.82 (82% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
69GF Score

Get the complete analysis for INDV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.82
Price
$22.98
GF Value